Loading…
← CockpitCompetitor Analysis › TRUALT.NS Trualt Bioenergy LimitedOpen in the cockpit ↗

Trualt Bioenergy LimitedTRUALT.NSCompetitor analysis, valuation and peers

India · INR·Chemicals›Chemicals: Specialty
Momentum laggard 2
Mkt cap
$309M
US dollars, full cap
Free float
19%
of shares outstanding
$/day
$995,852
20-day average traded
Fwd P/E
9.9×
forward earnings
ROIC−WACC
+0.2 pp
WACC 8.5%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · INR₹336.90
1D-0.9%
1W-2.8%
1M-23.7%
3M-29.0%
6M-27.1%
YTD-16.6%
1Y-30.2%
ATR %5.4%
Beta0.52
52w lowhigh37.8% off high

What Trualt Bioenergy does

Employees: 1,370

Trualt Bioenergy at a glance

Size Trualt Bioenergy (TRUALT.NS) is an India Materials company (Chemicals: Specialty) with a market value of $309M, the 1053rd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹336.90 on 18 Nov 2026.

Performance Over six months the shares fell 27.1%, against -30.4% for the median peer and +3.8% for the India market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue fell 5.2% over the last twelve months (peer median +9.5%); the operating margin is 14.3% (peer median 5.2%).

Valuation It trades at 9.9× forward earnings against a peer median of 9.3× (3rd most expensive of 7).

Capital Return on invested capital runs 0.2 points above its cost of capital (8.5% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 71TRUALT.NS 70
Six months, rebased to 100: Trualt Bioenergy against the median of its 20 peers (local-currency closes).

Trualt Bioenergy financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹27.5B₹16.7B₹17.6B₹12.2B₹7.62B
Revenue growth—-5%+44%+60%—
Gross profit₹7.92B₹2.59B₹2.32B₹1.88B₹1.36B
EBITDA₹4.87B₹2.36B₹1.65B₹1.88B₹1.05B
Net income₹2.21B₹959M₹1.47B₹318M₹355M
Free cash flown/a-₹9.59B-₹562M-₹4.24B-₹420M
Capital expendituren/a₹5.11B₹2.60B₹3.57B₹2.76B
Total debt₹16.6B₹16.5B₹15.6B₹16.8B₹11.5B

Quarterly statements and history in the cockpit →

Trualt Bioenergy competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-30%-20%-10%0%4027PREMEXPLN600319178920002136161000300538PCR4022603172104830002442301281ACT603722300437603968340570POLYPLEX6309TRUALT.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Trualt Bioenergy is the large dot.

Fundamentals: revenue growth against valuation

0%+10%8×10×12×178920PCR40221048303405706309TRUALT.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Trualt Bioenergy is the large dot.

Trualt Bioenergy competitors and peer comparison

How Trualt Bioenergy compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Trualt Bioenergy against its 20 peers (data as of 18 Nov 2026)
MeasureTRUALT.NSPeer medianRank in peer set
1-month return-23.7%-13.0%3rd lowest of 21
6-month return-27.1%-30.4%9th highest of 21
Distance from 52-week high-37.8%-46.0%7th highest of 21
Revenue growth (TTM)-5.2%+9.5%5th lowest of 21
Operating margin14.3%5.2%5th highest of 21
Forward P/E9.9×9.3×3rd most expensive of 7
ROIC minus cost of capital+0.2 pp-3.3 pp7th highest of 20
EV / EBITDA9.4×6.5×3rd most expensive of 11
Net debt / EBITDA3.4×0.1×2nd most indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Trualt Bioenergy TRUALT.NSIndia$309M-27%-5%14%9.9×n/an/a
Tayca 4027.TJapan$311M+20%+17%6%n/an/an/a
Premier Explosives PREMEXPLN.NSIndia$311M+3%-9%5%n/an/an/a
Weifang Yaxing Chemical 600319.SSChina$311M-32%-1%-9%n/an/an/a
PI Advanced Materials 178920.KSSouth Korea$307M-54%-2%22%9.0×-10.8%+0.1%
Anhui Annada Titanium Industry 002136.SZChina$306M-35%+12%2%n/an/an/a
Aekyung Chemical 161000.KSSouth Korea$313M-40%+16%3%n/an/an/a
Shenzhen Tongyi Industry 300538.SZChina$305M-34%-31%-3%n/an/an/a
PCC Rokita Spolka Akcyjna PCR.WAPoland$314M-11%-1%5%10.0×8.4%+4.1%
Rasa Industries,Ltd 4022.TJapan$315M-38%+16%12%9.6×7.7%+10.5%
Zhejiang Wanfeng Chemical 603172.SSChina$317M-30%+17%11%n/an/an/a
WONIK Materials 104830.KSSouth Korea$317M-31%+17%18%7.2×-8.3%+3.1%
Longxing Technology 002442.SZChina$319M-29%+7%1%n/an/an/a
Shandong Keyuan Pharmaceutical 301281.SZChina$298M-18%+33%15%n/an/an/a
Aduro Clean Technologies ACT.TOCanada$292M-41%-44%-13,483%n/an/an/a
Wuxi Acryl Technology 603722.SSChina$327M-43%+34%-15%n/an/an/a
Henan Qingshuiyuan Technology 300437.SZChina$327M-40%+13%-1%n/a26.9%-6.8%
Nantong Acetic Acid Chemical 603968.SSChina$290M-18%-1%-1%n/an/an/a
T&L 340570.KSSouth Korea$331M-1%-5%34%8.7×-15.9%+32.2%
Polyplex POLYPLEX.NSIndia$332M+11%+16%6%n/a17.3%+7.6%
Tomoe Engineering 6309.TJapan$333M+3%+2%9%12.5×n/an/a

Questions

Which companies are Trualt Bioenergy's closest peers?
The cockpit's peer set: Tayca (4027.T), Premier Explosives (PREMEXPLN.NS), Weifang Yaxing Chemical (600319.SS), PI Advanced Materials (178920.KS), Anhui Annada Titanium Industry (002136.SZ), Aekyung Chemical (161000.KS), Shenzhen Tongyi Industry (300538.SZ), PCC Rokita Spolka Akcyjna (PCR.WA).
Is Trualt Bioenergy expensive compared with its peers?
On forward p/e it trades at 9.9× against a peer median of 9.3×, 3rd most expensive of 7 in its peer set.
How has Trualt Bioenergy stock performed?
Over six months to 18 Nov 2026 the shares returned -27.1% against -30.4% for the median peer; over one year -30.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.